myTomorrows and Clínica Universidad de Navarra Collaborate to Enhance Clinical Trials with AI Technology

In a groundbreaking collaboration, the global health technology company myTomorrows has teamed up with Clínica Universidad de Navarra (CUN), a prestigious Spanish academic hospital, to revolutionize the landscape of clinical trials. This partnership marks a significant step in employing artificial intelligence (AI) to connect patients with pre-approval treatments, striving to improve trial matching efficacy and streamline referral processes.

The Challenge of Modern Clinical Trials

The complexity of current clinical trial portfolios cannot be underestimated. With numerous active cohorts, biomarker-defined subgroups, and ongoing recruitment updates, maintaining optimal patient-trial matching becomes challenging. At CUN, where more than 200 clinical trials are concurrently active, systematic review across the entire portfolio is vital. To address these challenges, the collaboration with myTomorrows introduces an AI-driven eligibility support system designed to integrate seamlessly within CUN's existing clinical practices.

Enhancements Through AI Integration

The newly introduced system harnesses the power of large language models (LLMs) to analyze clinical data, including structured variables such as diagnosis, staging, molecular profiles, and previous therapies, as well as unstructured medical documents in various languages. By systematically cross-referencing patient information against protocol-defined eligibility criteria and real-time cohort status, this approach enables clinicians to access a structured list of potentially eligible trials directly within each patient’s record.

Through this integration, CUN aims to significantly reduce the reliance on manual cross-referencing, which often results in overlooking specific trial arms or relevant biomarker-defined cohorts during clinical assessments. Moreover, this initiative supports consistent portfolio-level screening across various clinical workflows, including tumor boards and outpatient evaluations.

Phased Implementation for Clinical Relevance

To ensure that the AI matching capabilities align with clinical practices, CUN clinicians initially trialed the system within a secure, GDPR-compliant environment. This phase involved evaluating the system's performance on real clinical cases, allowing for adjustments and refinements. Following a successful evaluation, a secure API integration of the eligibility assessment functionality into CUN's electronic health record (EHR) and clinical trial management systems was established.

Streamlining Referrals

In addition to enhancing patient-trial matching, this partnership will improve referral coordination between CUN and external institutions. A newly developed CUN-branded website, powered by myTomorrows’ technology, will offer referring physicians insight into ongoing trials and real-time cohort statuses. In this secure environment, physicians will have the ability to AI-pre-screen potential patients against CUN’s trial portfolio, ensuring that referrals are based on the most current eligibility criteria and cohort availability.

This strategic alignment between referral processes and current trial standards will foster clearer communication, reduce administrative overhead, and consequently facilitate a more efficient pathway for patients seeking enrollment in clinical trials.

Looking to the Future

As the first partner site for myTomorrows in Spain, CUN will provide ongoing clinical and operational feedback, refining the partnership model within the context of its established excellence in research and technology adoption. This collaboration exemplifies a strategic approach to enhancing clinical trial operations through advanced AI capabilities, paving the way for future partnerships with institutions dedicated to improving patient access to innovative treatments.

Michel van Harten, CEO of myTomorrows, expressed enthusiasm about the partnership: “CUN's history of clinical research and commitment to technology makes it a valuable partner. As we work together, we aim to foster scalable solutions for clinical trial operations that can be adapted globally.” Likewise, Dr. Eduardo Castañón from CUN emphasized the importance of this collaboration in promoting technologies that streamline decision-making in an increasingly intricate healthcare environment.

With aspirations to further connect patients with innovative therapeutic options, this pioneering partnership between myTomorrows and CUN underscores a commitment to leveraging AI technology in the realm of clinical trials, ultimately aiming to simplify and accelerate access to critical medicines in development.